November 21, 2022 4:21pm

Also, a vacation one for me with a shortened closing bell’ report

Indication Results: 2 Hits and 3 Miss

News: Caribou Biosciences (CRBU -$0.17) has received clearance of its IND application from the U.S. FDA for CB-011, a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking. The CaMMouflage P1 clinical trial, a multicenter, open-label study to evaluate the safety and efficacy of a single dose of CB-011 in adult patients with relapsed or refractory multiple myeloma (r/r MM), is expected to initiate patient enrollment for treatment at dose level 1 (50x106 CAR-T cells) in early 2023.

It’s an honor to be considered the “canary in the (sector) coal mine”! It’s more than opinion, the facts and truth need to be recognized!

Ask yourself, do you know why you own certain equity?

 Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -45.41 points (-0.13%), the S&P close DOWN -15.40 points (-0.39%) while the Nasdaq closed DOWN -121.55 points (-1.09%)

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes shillyshallied Monday in a volatile session to start a short, holiday interrupted week due to Thanksgiving; as markets exhibited increased volatility and lower volumes into the final hour of trading as traders take time off.

 

Monday’s … RegMed Investor’s (RMi) Pre-Open: “key word: resistance. Thanksgiving week isn't necessarily a great time for any market move; volume will also be light throughout the short and holiday interrupted week.” … https://www.regmedinvestors.com/articles/12709

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened

  • Monday’s advance/decline line opened negative at 11 up/ 23 down and 1 flat, stayed negative with 5 up/ 30 down and 0 flat at the mid-day, ending with a negative close of 4/31 and 0 flat.

 

Pre-open Indications: 2 Hit < Solid Biosciences (SLDB -$0.04), Prime Medicine (PRME -$1.36)> 3 Miss < Regenxbio (RGNX -$0.04), Avrobio (AVRO +$0.03), Biostage (OTCQB: BSTG +$0.07)>

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -0.55% and the XBI was down -1.36%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.77. points or -3.33% at 22.35

 

Q4 – November

  • Monday closed negative with 4 incliner, 31 decliners and 0 flats

 

The BOTTOM LINE: I try to keep it simple … and short!

The Strange Case of Dr. Jekyll and Mr. Hyde might make for a great read, but it’s far less fun when the sector act like it’s their blueprint. Stocks have lately been alternating between the horrific and the benign.

Reiterating from this morning, “It’s Thanksgiving Week – supposedly a week to say “thanks”.

But, to WHOM?

NO thanks …to CEO Sue Washer and president (currently) of Applied Genetic Technologies (AGTC) for her “mistakes in management and judgement” during her tenure (let’s NOT forget her “bored” of directors) – who let her get away with such “mis-judgements” to have to sell-out the company for pennies as she executes her “exit package” of $1.5+ million having been paid $1.5 million to “wreck” the company this year.

Key word, uncertainty … “which makes It difficult to predict where the cell and gene therapy sector is headed in the short run.”

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash? I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.